Effect of antifungals on itraconazole resistant Candida glabrata

Central European Journal of Biology

Volumn 5, Issue 3, 2010, Pages 318-323

  Kucharíková, Soňa ^a,b,c   van Dijck, Patrick ^a,b   Lisalová, Magdaléna ^d   Bujdáková, Helena ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c Physics and Informatics   (Slovakia)

^d HPL sro Laboratory of Microbiology   (Slovakia)

Author keywords

Antifungal agents; Biofilm; Candida glabrata; Resistance

Indexed keywords

CANDIDA GLABRATA;

EID: 77952050537     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-010-0021-5     Document Type: Article

References (23)

1. Kaur R., Ma B., Cormack B. P., A family of glycosylphosphatidylinositol-linked spartyl proteases is required for virulence of Candida glabrata, Proc. Natl. Acad. Sci. USA, 2007, 104, 7628-7633.
2. Schelenz S., Ross C. N., Limitations of caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection, BMC Infect. Dis., 2006, 6, 126, doi: 10.1186/1471-2334-6-126.
3. Lee I., Fishman N. O., Zaoutis T. E., Morales K. H., Weiner M. G., Synnestvedt M., et al., Risk factors for fuconazole-resistant Candida glabrata bloodstream infections, Arch. Intern. Med., 2009, 169, 379-383.
4. Tumbarello M., Sanguinetti M., Trecarichi E. M., La Sorda M., Rossi M., de Carolis E., et al., Fungaemia caused by Candida glabrata with reduced susceptibility to fuconazole due to altered gene expression: risk factors, antifungal treatment and outcome, J. Antimicrob. Chemother., 2008, 62, 1379-1385.
5. Tsai H. F., Krol A. A., Sarti K. E., Bennett J. E., Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants, Antimicrob. Agents Chemother., 2006, 50, 1384-1392.
6. Wiederhold N. P., Najvar L. K., Bocanegra R., Molina D., Olivo M., Graybill J. R., In vivo effcacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera, Antimicrob. Agents Chemother., 2007, 51, 1616-1620.
7. Panackal A. A., Gribskov J. L., Staab J. F., Kirby K. A., Rinaldi M., Marr K. A., Clinical signifcance of azole antifungal drug cross-resistance in Candida glabrata, J. Clin. Microbiol., 2006, 44, 1740-1743.
8. Vandeputte P., Tronchin G., Rocher F., Renier G., Bergès T., Chabasse D., et al., Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth, Antimicrob. Agents Chemother., 2009, 53, 3034-3041.
9. Pfaller M. A., Messer S. A., Boyken L., Tendolkar S., Hollis R. J., Diekema D. J., Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002, J. Clin. Microbiol., 2004, 42, 3142-3146.
10. Petrikkos G., Skiada A., Recent advances in antifungal chemotherapy, Int. J. Antimicrob. Agents, 2007, 30, 108-117.
11. Brzankalski G. E., Najvar L. K., Wiederhold N. P., Bocanegra R., Fothergill A. W., Rinaldi M. G., et al., Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility, J. Antimicrob. Chemother., 2008, 62, 1094-1100.
12. Seneviratne C. J., Silva W. J., Jin L. J., Samaranayake Y. H., Samaranayake L. P., Architectural analysis, viability, assesment and growth kinetics of Candida albicans and Candida glabrata bioflms, Arch. Oral. Biol., 2009, 54, 1052-1060.
13. Silva S., Henriques M., Martins A., Oliveira R., Williams D., Azeredo J., Bioflms of non-Candida albicans Candida species: quantifcation, structure and matrix composition, Med. Mycol., 2009, 47, 681-689.
14. Song J. W., Shin J. H., Kee S. J., Kim S. H., Shin M. G., Suh S. P., et al., Expression of CgCDR1, CgCDR2, and CgERG11 in Candida glabrata bioflms formed by bloodstream isolates, Med. Mycol., 2009, 47, 545-548.
15. Al-Fattani M. A., Douglas L. J., Penetration of Candida bioflms by antifungal agents, Antimicrob. Agents Chemother., 2004, 48, 3291-3297.
16. Al-Dhaheri R. S., Douglas L. J., Absence of amphotericin B-tolerant persister cells in bioflms of some Candida species, Antimicrob. Agents Chemother., 2008, 52, 1884-1887.
17. National Committee for Clinical Laboratory Standards, Reference method for broth dilution antifungal susceptibility testing of yeast, Approved standard M27-A3, National Committee for Clinical Laboratory Standards, Wayne, PA, 2008.
18. Li X., Yan Z., Xu J., Quantitative variation of bioflms among strains in natural populations of Candida albicans, Microbiology, 2003, 149, 353-362.
19. Borecká-Melkusová S., Moran G. P., Sullivan D. J., Kucharíková S., Chorvát D. Jr., Bujdáková H., The expression of genes involved in the ergosterol biosynthesis pathway in Candida albicans and Candida dubliniensis bioflms exposed to fuconazole, Mycoses, 2008, 52, 118-128.
20. Hitchcock C. A., Pye G. W., Troke P. F., Johnson E. M., Warnock D. W., Fluconazole resistance in Candida glabrata, Antimicrob. Agents Chemother., 1993, 37, 1962-1965.
21. Sanglard D., Ischer F., Calabrese D., Majcherczyk P. A., Bille J., The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents, Antimicrob. Agents Chemother., 1999, 43, 2753-2765.
22. Barchiesi F., Spreghini E., Tomassetti S., Arzeni D., Giannini D., Scalise G., Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata, Antimicrob. Agents Chemother., 2005, 49, 4989-4992.
23. Cateau E., Rodier M., Imbert Ch., In vitro effcacies of caspofungin or micafungin catheter lock solutions on Candida albicans bioflm growth, J. Antimicrob. Chemother., 2008, 62, 153-155.